Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Skin and Connective Tissue Diseases

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Prostatic Neoplasms

Breast Neoplasms

Lymphoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

7-hydroxystaurosporine

Protein Kinase Inhibitors

Enzyme Inhibitors

7-hydroxystaurosporine (UCN-01)

This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits.

Patients with relapsed or refractory neoplasms will be treated with escalating doses of UCN-01(7-hydroxystaurosporine) a protein kinase C inhibitor which also may affect cyclin-dependent kinase activity, given as a 72 hour infusion. This trial will determine the toxicity associated with the maximally tolerated dose of this drug in patients for whom no other therapeutic approach is deemed to be more useful.

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

National Cancer Institute (NCI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms	NCT00001444	Breast Cancer Lymphoma Neoplasm Prostatic Neopl...	7-hydroxystauro...	-	National Institutes of Health Clinical Center (CC)
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms	NCT00001444	Breast Cancer Lymphoma Neoplasm Prostatic Neopl...	7-hydroxystauro...	-	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for natural products